Chordoma Clinical Trial
Official title:
Title of Study: SAcral Chordoma: a Randomized & Observational Study on Surgery Versus Definitive Radiation Therapy in Primary Localized Disease (SACRO)
Comparative study on surgery versus definitive radiation therapy in primary localized sacral chordoma
International, multicenter, comparative, open-label, parallel-group, mixed Observational-Randomized Controlled Trial. All the patients, who are candidate for the study will receive full information on the characteristics, potential effectiveness and side effects of the two alternatives treatments: radiotherapy (RT) and surgical treatment Eligible patients will be asked to be randomized in order to receive treatment A (surgery, with or without RT) or treatment B (definitive RT) Who will refuse randomization will be included in the Prospective Cohort Study (PCS) and will be treated accordingly to their choice (treatment option A or treatment option B). The same radiotherapy and surgical regimen will be administered in the PCS and in the Randomized Clinical Trial (RCT) cohort ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03955042 -
Pemetrexed for the Treatment of Chordoma
|
Phase 1 | |
Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
Active, not recruiting |
NCT00496119 -
Proton Beam Therapy for Chordoma Patients
|
Phase 2 | |
Recruiting |
NCT06029218 -
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
|
N/A | |
Completed |
NCT03595228 -
BN Brachyury and Radiation in Chordoma
|
Phase 2 | |
Recruiting |
NCT06140732 -
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
|
Phase 2 | |
Active, not recruiting |
NCT01175109 -
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
|
Phase 1 | |
Completed |
NCT00150072 -
Efficacy and Safety of Imatinib in Chordoma
|
Phase 2 | |
Terminated |
NCT00003926 -
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05041127 -
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
|
Phase 2 | |
Recruiting |
NCT05861245 -
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
|
N/A | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT02383498 -
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
|
Phase 2 | |
Recruiting |
NCT03242382 -
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
|
Phase 2 | |
Completed |
NCT02520128 -
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
|
N/A | |
Recruiting |
NCT01567046 -
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
|
N/A | |
Completed |
NCT00919269 -
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
|
||
Active, not recruiting |
NCT02989636 -
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
|
Phase 1 | |
Active, not recruiting |
NCT03083678 -
Afatinib in Locally Advanced and Metastatic Chordoma
|
Phase 2 | |
Completed |
NCT00713037 -
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
|
N/A |